New hope for cancer patients: drug may prevent chemo delays by boosting platelets
NCT ID NCT07408648
First seen Feb 14, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tests a pill called hetrombopag in 244 women with gynecological cancers (like ovarian or cervical) whose platelet counts drop dangerously low after chemotherapy. The goal is to see if the drug can safely bring platelet levels back up and keep them stable through the next chemo cycle, reducing the need for transfusions or treatment delays. Participants will take hetrombopag daily until their platelets recover, with some starting right away and others only when counts fall again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.